RTP Mobile Logo
Gastrointestinal Cancer Update, Issue 1, 2012
Released April 2012

Featuring interviews with Drs Eric Van Cutsem, David P Ryan, Ghassan Abou-Alfa and Dirk Arnold. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Colorectal cancer (CRC) is a common and potentially lethal type of cancer, and its clinical management is continuously evolving. Although “non-CRC” gastrointestinal (GI) tumors are less frequently encountered individually, the cancer-related deaths in that subcategory surpass those attributed to CRC. Published results from ongoing trials continuously lead to the emergence of novel biomarkers and new therapeutic targets and regimens, thereby altering existing management algorithms. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Gastrointestinal Cancer Update uses one-on-one discussion with leading GI oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.

    LEARNING OBJECTIVES

    • Effectively apply the results of practice-changing clinical research to the selection and sequencing of chemobiologic regimens for patients with metastatic colorectal cancer.
    • Summarize key findings from clinical studies of emerging therapeutic regimens for pancreatic cancer and utilize this information to guide treatment decision-making for patients.
    • Counsel patients with Stage II colon cancer about their individual risk of recurrence based on clinical, pathologic and genomic biomarkers, and consider adjuvant therapeutic options.
    • Use clinical and molecular biomarkers to optimize systemic treatment of gastric and gastroesophageal cancer.
    • Communicate the benefits and risks of existing and emerging systemic therapeutic interventions to patients with advanced hepatocellular carcinoma.
    • Counsel appropriately selected patients with GI cancer about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CREDIT DESIGNATION STATEMENT


    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Prof Van CutsemResearch Grants: Amgen Inc, Merck Serono, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc. Dr RyanAdvisory Committee: Genomic Health Inc. Dr Abou-AlfaConsulting Agreements: Abbott Laboratories, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celsion Corporation, Chugai Pharmaceutical Co Ltd, Clovis Oncology, Daiichi Sankyo Inc, Genentech BioOncology, GenVec Inc, Halozyme Therapeutics, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Jennerex Inc, MediGene Inc, Merck and Company Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi; Paid Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Chugai Pharmaceutical Co Ltd, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, MediGene Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Polaris Group. Dr ArnoldAdvisory Committee: Amgen Inc, Merck Serono, Roche Laboratories Inc, Sanofi; Consulting Agreement: Bayer HealthCare Pharmaceuticals; Paid Research: Roche Laboratories Inc; Speakers Bureau: Amgen Inc, Merck Serono, Roche Laboratories Inc, Sanofi.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Inctye Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.


    This activity is supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Regeneron Pharmaceuticals and Sanofi.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2012
    Expiration date: April 2013

Acknowledge and close

Listen to audio:
Gastrointestinal Cancer Update, Issue 1, 2012
Released April 2012

Featuring interviews with Drs Eric Van Cutsem, David P Ryan, Ghassan Abou-Alfa and Dirk Arnold. (Text and Audio Content)

Read print: